Neurology-focused Brenig Therapeutics raises $65M in series A financing

Brenig Therapeutics, a Dover, DE-based neurology-focused drug development company utilizing an AI/ML-based discovery platform, raised $65M in Series A funding.

The round was led by NEA, with participation from OrbiMed, Torrey Pines Investments and BioGeneration Ventures. In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.